{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:20:46Z","timestamp":1783707646987,"version":"3.55.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"11","license":[{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Blastic plasmacytoid\u00a0dendritic cell neoplasm (BPDCN) can involve skin, bone marrow (BM), central nervous system (CNS), and non-CNS extramedullary sites. Preclinical models demonstrated clonal advantage of\u00a0TET2-mutated plasmacytoid dendritic cells exposed to UV radiation. However, whether sun exposure, disease characteristics, and patient survival are clinically related is unclear. We classified organ involvement in 66 patients at diagnosis as skin only (n =\u00a019), systemic plus skin (n\u00a0=\u00a033), or systemic only (n\u00a0=\u00a014). BM involvement was absent, microscopic (&amp;lt;5%), or overt (\u22655%). UV exposure was based on clinical and demographic data. Patients with skin only BPDCN were more frequently aged\u00a0\u226575 years (47% vs 19%;\u00a0P\u00a0=\u00a0.032) and had lower rates of complex karyotype (0 vs 32%,\u00a0P\u00a0=\u00a0.022) and mutated\u00a0NRAS\u00a0(0 vs 29%,\u00a0P\u00a0=\u00a0.044). Conversely, those without skin involvement had lower UV exposure (23% vs 59%,\u00a0P\u00a0=\u00a0.03) and fewer\u00a0TET2\u00a0mutations (33% vs 72%,\u00a0P\u00a0=\u00a0.051). The median overall survival (OS) was 23.5, 20.4, and 17.5\u00a0months for skin only, systemic plus skin, and systemic only, respectively. Patients with no BM involvement had better OS vs\u00a0overt involvement (median OS, 27.3 vs 15.0\u00a0months;\u00a0P\u00a0=\u00a0.033) and comparable with microscopic involvement (27.3 vs 23.5\u00a0months;\u00a0P\u00a0=\u00a0.6). Overt BM involvement remained significant for OS when adjusted for baseline characteristics and treatment received. In summary, BPDCN clinical characteristics are associated with disease genetics and survival, which together may impact prognosis and indicate informative disease subtypes for future research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012797","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T19:01:10Z","timestamp":1712862070000},"page":"2803-2812","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Organ involvement in adults with BPDCN is associated with sun exposure history, <i>TET2<\/i> and <i>RAS<\/i> mutations, and survival"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-9652","authenticated-orcid":false,"given":"Shai","family":"Shimony","sequence":"first","affiliation":[{"name":"1Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Rabin Medical Center and Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Keating","sequence":"additional","affiliation":[{"name":"3Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3278-1417","authenticated-orcid":false,"given":"Christopher J.","family":"Fay","sequence":"additional","affiliation":[{"name":"4Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"5Center for Cutaneous Oncology, Dana-Farber Brigham Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-4529","authenticated-orcid":false,"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna S.","family":"Neuberg","sequence":"additional","affiliation":[{"name":"3Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8264-834X","authenticated-orcid":false,"given":"Nicole R.","family":"LeBoeuf","sequence":"additional","affiliation":[{"name":"4Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"5Center for Cutaneous Oncology, Dana-Farber Brigham Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7380-0226","authenticated-orcid":false,"given":"Andrew A.","family":"Lane","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"issue":"5","key":"2024061016105733300_bib1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1309\/FY6PK436NBK0RYD4","article-title":"CD4+\/CD56+ hematodermic tumor","volume":"127","author":"Herling","year":"2007","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"2024061016105733300_bib2","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1182\/blood.V97.10.3210","article-title":"Identification of a leukemic counterpart of the plasmacytoid dendritic cells","volume":"97","author":"Chaperot","year":"2001","journal-title":"Blood"},{"issue":"24","key":"2024061016105733300_bib3","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1182\/bloodadvances.2019000647","article-title":"How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?","volume":"3","author":"Garnache-Ottou","year":"2019","journal-title":"Blood Adv"},{"issue":"7966","key":"2024061016105733300_bib4","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-023-06156-8","article-title":"Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin","volume":"618","author":"Griffin","year":"2023","journal-title":"Nature"},{"issue":"4","key":"2024061016105733300_bib5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ajh.2830470406","article-title":"High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma","volume":"47","author":"Adachi","year":"1994","journal-title":"Am J Hematol"},{"issue":"1","key":"2024061016105733300_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/PAS.0b013e3181c5e26b","article-title":"Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients","volume":"34","author":"Cota","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"2024061016105733300_bib7","doi-asserted-by":"crossref","first-page":"10174","DOI":"10.18632\/oncotarget.7101","article-title":"Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy","volume":"7","author":"Mart\u00edn-Mart\u00edn","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"2024061016105733300_bib8","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.2019001144","article-title":"Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark","volume":"134","author":"Taylor","year":"2019","journal-title":"Blood"},{"issue":"14","key":"2024061016105733300_bib9","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/bloodadvances.2020001875","article-title":"Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant","volume":"4","author":"Yun","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"2024061016105733300_bib10","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1182\/bloodadvances.2022007879","article-title":"TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm","volume":"7","author":"Beird","year":"2023","journal-title":"Blood Adv"},{"issue":"26","key":"2024061016105733300_bib11","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024061016105733300_bib12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood.2022017865","article-title":"North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need","volume":"141","author":"Pemmaraju","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2024061016105733300_bib13","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ajh.23567","article-title":"TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow","volume":"88","author":"Alayed","year":"2013","journal-title":"Am J Hematol"},{"issue":"1","key":"2024061016105733300_bib14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/jha2.617","article-title":"Biallelic TET2 mutations and canonical ASXL1 mutations are frequent and cooccur in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): an institutional experience and review of literature","volume":"4","author":"Zhang","year":"2023","journal-title":"EJHaem"},{"issue":"5","key":"2024061016105733300_bib15","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/s41375-022-01538-9","article-title":"Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients","volume":"36","author":"Khanlari","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"2024061016105733300_bib16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s12185-018-2461-z","article-title":"Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis","volume":"108","author":"Suma","year":"2018","journal-title":"Int J Hematol"},{"issue":"15","key":"2024061016105733300_bib17","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMra0804615","article-title":"DNA damage, aging, and cancer","volume":"361","author":"Hoeijmakers","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024061016105733300_bib18","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.3390\/molecules19056202","article-title":"Ultraviolet radiation, aging and the skin: prevention of damage by topical cAMP manipulation","volume":"19","author":"Amaro-Ortiz","year":"2014","journal-title":"Molecules"},{"issue":"1","key":"2024061016105733300_bib19","doi-asserted-by":"crossref","first-page":"100352","DOI":"10.1016\/j.modpat.2023.100352","article-title":"Cutaneous manifestations of myeloid neoplasms exhibit broad and divergent morphologic and immunophenotypic features but share ancestral clonal mutations with bone marrow","volume":"37","author":"Sadigh","year":"2024","journal-title":"Mod Pathol"},{"issue":"5","key":"2024061016105733300_bib20","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/bloodadvances.2020003359","article-title":"Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis","volume":"5","author":"Renosi","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"2024061016105733300_bib21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41408-019-0262-0","article-title":"Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"9","author":"Beird","year":"2019","journal-title":"Blood Cancer J"},{"issue":"2","key":"2024061016105733300_bib22","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/2159-8290.CD-20-1513","article-title":"Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis","volume":"12","author":"Togami","year":"2022","journal-title":"Cancer Discov"},{"issue":"10","key":"2024061016105733300_bib23","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/bloodadvances.2021006645","article-title":"Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD","volume":"6","author":"Pemmaraju","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2024061016105733300_bib24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/DAD.0b013e318280de99","article-title":"Blastic plasmacytoid dendritic cell neoplasm: evolving insights in an aggressive hematopoietic malignancy with a predilection of skin involvement","volume":"36","author":"Gera","year":"2014","journal-title":"Am J Dermatopathol"},{"issue":"2","key":"2024061016105733300_bib25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.2012.072645","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/11\/2803\/2228317\/blooda_adv-2024-012797-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/11\/2803\/2228317\/blooda_adv-2024-012797-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T16:11:28Z","timestamp":1718035888000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/11\/2803\/515717\/Organ-involvement-in-adults-with-BPDCN-is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,6,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012797","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]}}}